Amgen Inc. plans to spend $420 million to acquire Ilypsa Inc., a privately held developer of treatments for kidney disorders, the companies announced late Monday.
Santa Clara-based Ilypsa's lead drug candidate is designed to counter abnormally high levels of phosphate that can occur in the blood of chronic kidney disease patients on dialysis. Because the drug, called ILY101, is not absorbed by the body, it has the potential for being safer and better tolerated than other treatments. The drug has completed mid-stage clinical trials.
Thousand Oaks-based Amgen said the deal has been approved by both boards and by Ilypsa shareholders. The transaction is expected to close in the third quarter.
Amgen shares closed down 3 cents to $56.91 Monday on the Nasdaq.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Amgen Acquires Alantos for $300 Million
- Amgen Deal May be First of Many
- Amgen to Buy Developer of Promising Kidney Drug
- Amgen, Allergan Launch Cancer Biosimilars in U.S. Market
- Amgen Completes Acquisition of Kidney Drug Developer
- Amgen Drug Off Medicare List
- Amgen Buys Dezima and Signs Xencor Research Deal
- FDA Panel Gives Amgen Hopeful Aranesp News